RUA BIOSCIENCE

Hui a Tau

Annual Shareholders Meeting

28 October 2025

Rua Bioscience Limited (Rua) is a New Zealand pharmaceutical company aiming to be a leading distributor of cannabinoid derived medicines. This presentation and the information contained in or accompanying this presentation are not, and are under no circumstances to be construed as, an invitation to subscribe for, or an offer of, shares, securities or financial products to any person, in any country or the basis for a contract, financial advice, other advice or recommendation to conclude any transaction for the purchase or sale of any security, loan or other instrument. This presentation has not been independently verified. Neither Rua nor any of its directors, officers, shareholders, advisors, agents or employees make any representation or warranty as to the accuracy or completeness of the information contained in this presentation and those parties shall have no liability for any statement, opinion, information or matters arising out of, contained in, or for any omissions from, or failure to correct or update any information in, this presentation or any other communications transmitted to you in relation to this presentation.

How to Participate in Virtual/ Hybrid Meetings and Ask a Question

Shareholder & Proxyholder Q & A Participation

Online Questions

- If you have a **question** to submit during the live meeting, please select the **Q & A tab on the right half of your screen at anytime.** Type your question into the field and press submit. Your question will be immediately submitted to the moderator.

Help

- The **Q & A tab can also be used for immediate help.** If you need assistance, please submit your query in the same manner as typing a question and a Computershare representative will respond directly to you.



How to Participate in Virtual/ Hybrid Meetings and Vote

Shareholder & Proxyholder Voting

- Once the **voting** has been opened, the resolutions and voting options will allow voting.
- To vote, simply **click on the Vote tab**, and **select your voting direction from the options shown** on the screen.
- Your vote has been cast when the **tick** appears.
- To **change** your vote, select 'Change Your Vote'.



Board of Directors Te Poari Ringatohu

Anna Stove

Chair

A 25+ years track record leading transformational change within the pharmaceutical sector, having held senior executive roles in NZ, Asia Pacific and Europe.

Panapa Ehau

Executive Director, Co-Founder

Co-founder of a number of social enterprises. Holds governance roles across numerous for-profit and charitable organisations.

Teresa Ciprian

Non-Executive Director

Global expertise in innovation, commercialisation, marketing and business development in the primary sector.

Tony Barclay

Non-Executive Director

Over 30 years' experience in business, with 22 years of healthcare expertise. Holds Directorships in private MedTech companies.

Kale Panoho

Board Observer

An entrepreneur at heart having started multiple successful technology businesses out of the US and NZ.

Agenda
Rarangi take

1. Company overview and Chair's address
2. Chief Executive Officer's presentation
3. Annual results presentation
4. Shareholder questions
5. Ordinary resolutions
    1. Auditor's remuneration
    2. Re-election of Teresa Ciprian as Director
    3. Ratification of issued shares
    4. Issue of new Ordinary Shares
6. General business

Company overview and Chair's address

Te tirohanga whanui o te kamupene me te korero a te Heamana

Strategy to Execution
E kokiri ana ki te kaupapa

RUA

Partner with best in class for low cost, scalable delivery.

RUA

Germany | Australia | UK
Aotearoa New Zealand
Czechia

Revenue from customers
$1.5m

Commercial Momentum

Revenue
$1.9m

Cost Control

Opex
$3.4m

Shareholder Support

Equity and debt
$1.9m

Achievements at a glance

Mawhiti mai ki nga whakatutukitanga

- Launched a new product in Australia leveraging New Zealand legacy genetics
- Expanded the German product portfolio at a pivotal point in the market.
- Delivered strong revenue growth across three key markets
- Secured alignment with leading clinic chains in Australia to drive revenue.
- Broadened the approved product range in Aotearoa, New Zealand.
- Established a new UK sales pipeline in partnership with Target Healthcare.

Subsequent activity

- Entry into the Czech market in early FY26 with the launch of Rua's first product.

Rua requires additional capital to fund growth opportunities

Rua is seeking to raise ~$2m of new equity

- Working capital funding for growth

- The cash raised, both from the facility sale and capital raise, is intended (if fully subscribed) to fund the business to a self-sustaining position.

Chief Executive Officer’s presentation

Te whakatakotoranga o te Kaiwhakakahaere Matua

RUA

FY25: An overview

Tirohanga whanui

$1.9m

Total Revenue

17

Products

5

Markets

We have reduced operational expenditure and increased sales revenue

Operational expenditure



Sales revenue





Global progress
Kokiri ki te ao

●	Aotearoa New Zealand	Three product approvals to date
●	Australia	Growing sales due to strong clinic relationships
●	United Kingdom	Established product supply for distribution
●	Germany	Increase sales revenue significantly with new product launches
●	Poland	Work continues on appropriate product supply channels.
●	Czechia	Product launched in Q1 FY26

Australia is a significant opportunity

- Rua increased revenue to $585k
- One of the larger medicinal cannabis markets in the world at approximately $900m.
- Expanded our reach through new distribution channels and clinic networks.
- Expanded the portfolio during the year to include new product formats and legacy genetic from Aotearoa.



Units prescribed

Germany is the largest market

- Largest and most developed medicinal cannabis market in Europe, if not the world.
- Considerable growth in the market, including imports.
- Significantly grew revenue to $487k
- August 25 we successfully launched a new dried flower product cultivated in New Zealand.

RUA BIOSCIENCE

United Kingdom has considerable growth potential

- Early stage market with considerable growth potential.
- Established a supply pipeline meeting the necessary regulatory requirements.
- Introduced three oil products for prescription.
- New products expected in FY26



Czechia: We are strategically one of the early entrants

- Changes to regulations in April 2025 have allowed GP's to prescribe medicinal cannabis.
- Established supply channel with distribution partner, Motgaon.
- First sales of product in September 2025

Aotearoa, New Zealand is small but key to our Rua brand

- Significantly grew revenue to $440k
- Additional new product approved
- Two further product applications have been initiated.



We continue to support up to 52 patients per month through our Compassionate Access Programme



Our Scholarship Programme is inspiring rangatahi

In FY25 we leveraged our network to help and inspire local rangatahi

Trust Tairāwhiti
Regional Wellbeing
He Tohu Ora

13	Scholarships
2	Industry trips
1	Internship
3	Kura visits to Mangaoporo

Rua's FY25 GHG report

Te ripoata GHG o Rua mo FY25

Scope 1 and 2 emissions reduced by 20%

Scope 3 emissions growing as our revenue grows



Our plans for FY26 are to significantly grow revenue

Te mahere o Rua FY26

Revenue from customers

$3–5 mill

New products

New products in all markets

New markets

Czechia

RUA BDO

FY25 financial commentary

Nga korero mo nga putea

Profit & loss
Nga korero mo nga putea

Rua's annual financial results for the year ended 30 June 2025.

Rua establishes in all markets

Revenue from customers

$1.5m

Total revenue and other income

$1.9m

Loss before tax

-$3.5m

Balance sheet
Nga korero mo nga putea

Rua's annual financial results for the year ended 30 June 2025.

Rua requires further capital

Cash and investments

$241k

Total assets

$6.78m

Total liabilities

$1.89m

Net assets

$4.89m

Cashflow
Nga korero mo nga putea

Rua's annual financial results for the year ended 30 June 2025.

Investing in the future

Net cash outflow from operating activities

$2.79m

Net cash inflow from investing activities

$0.11m

Net cash inflow from financing activities

$2.02m

Operational expenditure is reducing
Nga korero mo nga putea

Rolling 12-month, average monthly expenditure



Sales Revenue is growing
Nga korero mo nga putea

Quarterly sales revenue, all markets



Shareholder questions
Nga patai a nga kaipupuri hea

Ordinary resolutions
Whakataunga noa

RUA

Resolution One

That the Board be authorised to fix the auditor's remuneration.

RUA

Resolution Two

That Teresa Ciprian be re-elected as a Director of Rua

RUA

Resolution Three

To ratify the prior issue of Ordinary Shares and Warrants

- 16,799,999 ordinary shares
- 5,926,673 warrants

RUA

Resolution Four

That the Board are authorised to issue New Shares if required

- Up to 49,993,744 shares
- At a price of not less than 3c per share
- At any time during the next 12 months

General business

Nga take hakirikiri

RUA

BIOSCIENCE